Here are five observations:
1. K2M stock currently has a consensus rating of “buy” and a consensus price target of $28.75.
2. The company has a 52-week low of $12.31 and a 52-week high of $26.29.
3. K2M’s 50-day moving average is $23.76 and its 200-day moving average is $22.44.
4. K2M also reported an 18.7 percent revenue increase in the second quarter of 2015.
5. K2M revenue was $56.4 million for the second quarter. International revenue was up 4.5 percent to $14.9 million while domestic revenue was up 24.7 percent to $41.4 million.
More articles on devices:
InVivo’s Q2 net loss hits $10.4M as spinal cord injury trial shows early success: 5 things to know
InVivo Therapeutics promotes 2 to bolster spinal cord injury innovation: 5 points
LDR revenue up 19.4%, net loss at $5.8M: 10 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
